Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fast, Accurate Test Aids in Detection of Lynch Syndrome

By LabMedica International staff writers
Posted on 04 Apr 2023

Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, with around 3-5% of cases attributed to Lynch syndrome - an uncommon hereditary cancer predisposition syndrome that elevates the risk of developing CRC. More...

The current guidelines for cancer treatment emphasize the significance of testing for Mismatch Repair (MMR) status in all newly diagnosed CRCs as an initial screening procedure for Lynch syndrome. Immunohistochemistry (IHC), an increasingly prevalent clinical practice, is one of the suggested methods of testing.

Leica Biosystems’ (Nussloch, Germany) US FDA-cleared BOND MMR Antibody Panel now offers a high-performing IHC MMR option when screening CRC patients for identifying probable Lynch syndrome. The BOND MMR Antibody Panel is now available for clinical use on the BOND-III and BOND-MAX IHC automated instruments.

"Pathologists can utilize the Leica Biosystems BOND MMR Antibody Panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours," said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems. "With this panel, clinicians can feel increased confidence in their MMR results."

"Leica Biosystems is proud to help our customers continue the fight against cancer through the fast, accurate results of the BOND MMR Antibody Panel, which provides the clinicians an important piece of the diagnostic puzzle in aiding the detection of Lynch syndrome," added Gustavo Perez-Fernandez, President of Leica Biosystems. "Our test enables targeted treatment for patients, supporting our mission of Advancing Cancer Diagnostics, Improving Lives."

Related Links:
Leica Biosystems


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.